Fatih Gürler

12PUBLICATIONS
46CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsAutoimmunitySolid tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|May 04, 2026
Clinicopathological Predictors of Pathological Complete Response in HER2-Positive Breast Cancer Treated with Pertuzumab-Based Neoadjuvant Therapy: A Multicenter Real-World Study.

|Dec 26, 2025
Immunomodulatory Effect of First-Line Cisplatin Versus Carboplatin in Response to Second-Line Nivolumab Therapy in Metastatic Non-Small Cell Lung Cancer.

Orhun Akdogan, Hatice Bolek, Kadriye Baskurt

|May 06, 2025
Splenic index score as a predictor of outcomes in metastatic non small cell lung cancer patients treated with immune checkpoint inhibitors.

Volkan Aslan, Atiye Cenay Karabörk Kılıç, Nigar Rustamova Cennet

|Jul 20, 2024
A propensity score-matched comparison of neoadjuvant chemoradiotherapy with cisplatin-5FU and carboplatin-paclitaxel in locally advanced esophageal squamous cell carcinoma: A Turkish oncology group study.

Fatih Gürler, Fatih Tay, Zehra Sucuoğlu İşleyen

|Jun 27, 2024
Prognostic Role of OX40, LAG-3, TIM-3 and PD-L1 Expression in Bone and Soft Tissue Sarcomas.

Bediz Kurt İnci, Elif Acar, Fatih Gürler

|Mar 15, 2024
Retrospective Analyses of PD-L1, LAG-3, TIM-3, OX40L Expressions and MSI Status in Gastroenteropancreatic Neuroendocrine Neoplasms.

Fatih Gürler, Selin Aktürk Esen, Bediz Kurt İnci

Pageof 2

Frequent Collaborators

8 joint publications

Ozan Yazıcı

6 joint publications

Osman Sütcüoğlu

6 joint publications

Bediz Kurt İnci

5 joint publications

Nuriye Özdemir